PSI Advisors’s Axsome Therapeutics AXSM Stock Holding History

PSI Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40	Closed	-$4.67K	–	148
2025 Q1	$4.67K	Hold	40	–	–	﹤0.01%	534
2024 Q4	$3.38K	Hold	40	–	–	﹤0.01%	670
2024 Q3	$3.6K	Hold	40	–	–	﹤0.01%	697
2024 Q2	$3.22K	Hold	40	–	–	﹤0.01%	682
2024 Q1	$3.19K	Hold	40	–	–	﹤0.01%	634
2023 Q4	$3.18K	Buy	+40	New	+$2.67K	﹤0.01%	681

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PSI Advisors's AXSM Position: Q2 2025 in Review

PSI Advisors sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 40 shares — an estimated $4.67K sold.

PSI Advisors first reported a position in AXSM in Q4 2023 and held it in 6 quarters. The position peaked at $4.67K in Q1 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

PSI Advisors reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
PSI Advisors sold 40 Axsome Therapeutics shares in Q2 2025, an estimated $4.67K.
PSI Advisors first reported a position in Axsome Therapeutics in Q4 2023 and held it in 6 quarters.
PSI Advisors's Axsome Therapeutics position peaked at $4.67K in Q1 2025.
348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on PSI Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.